Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
New Novartis Fabhalta® (iptacopan) data show clinically meaningful and…
APPLAUSE-IgAN is first and only Phase III study to demonstrate significant proteinuria reduction by targeting the complement system in patients with IgAN 1 IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide 2 ; complement activation is a key driver of glomerular inflammation in IgAN 3,4 There is a need for effective, targeted therapies for IgAN 2,5 ; up to 30% of patients with persistent proteinuria (≥1...
Nasdaq GlobeNewswire
15/04/2024
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives…
Bagsværd, Denmark, 15 April 2024— This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company's board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk...
Nasdaq GlobeNewswire
15/04/2024
Publication Annual Report – Annual Shareholders' Meeting
Publication Annual Report – Annual Shareholders' MeetingLeuven, BELGIUM – April 15, 2024 – 05:00 PM CETOxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, has today published its annual report for the financial year 2023. The annual report for the year ending December 31, 2023 is available in the “Investors” section of the Company's website, and can also be downloaded as a PDF.On this day as well, the Company has convened its Annual Shareholders'...
Nasdaq GlobeNewswire
15/04/2024
Craniofacial Implants Market to reach $118.2 million, Globally, by 2032 at 8.3%…
Request Sample of the Report on Craniofacial Implants Market Forecast - https://www.alliedmarketresearch.com/request-sample/A295583 Request Sample of the Report on Craniofacial Implants Market Forecast -https://www.alliedmarketresearch.com/request-sample/A295583 Prime determinants of growth The craniofacial implants market has experienced significant growth owing to technological advancements in the craniofacial implant technology, rise in incidence of facial fractures due to...
PR Newswire
15/04/2024
Core Clinical Molecular Diagnostics Market to Reach $11.9 Billion, Globally, by…
Request Sample of the Report on Core Clinical Molecular Diagnostics Market Forecast - https://www.alliedmarketresearch.com/request-sample/A323203 Request Sample of the Report on Core Clinical Molecular Diagnostics Market Forecast -https://www.alliedmarketresearch.com/request-sample/A323203 Prime determinants of growth Growth in the adoption of molecular diagnostics, advancements in technologies, and presence of key players are the factors that drive the growth of the global core...
PR Newswire
15/04/2024
Norgine B.V. submits Marketing Authorisation Application via Project Orbis for…
On 13 December 2023, the US Food and Drug Administration (FDA) approved eflornithine as the first oral maintenance therapy for high-risk neuroblastoma (HRNB), indicated to reduce the risk of relapse in adult and paediatric patients who have received certain prior therapies.1 The approval decision was based on findings from a trial comparing outcomes from Study 3b (NCT02395666; investigational arm)2,4 and Study ANBL0032 (NCT00026312; clinical-trial-derived external control arm)3,4, where use of…
PR Newswire
15/04/2024
Robotic Radiotherapy Market Worth $1.9 billion | MarketsandMarkets™
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=122256158 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=122256158 Browse in-depth TOC on "Robotic Radiotherapy Market" 180 - Tables45 - Figures270 - Pages Robotic Radiotherapy Market Scope: The 3D cameras (SGRT) segment is expected to register the highest growth in the forecast period of 2023-2028. Based on the product, the...
PR Newswire
15/04/2024
Body Mist Market to Reach $12.6 billion, Globally, by 2032 at 5.2% CAGR: Allied…
Prime determinants of growth Prime determinants of growth The burgeoning emphasis on wellness and self-care routines has become an important aspect of contemporary lifestyles, thus driving the demand for products that cater to holistic well-being. Body mists, with their refreshing fragrances and therapeutic benefits, have emerged as a favored choice among consumers seeking moments of relaxation and rejuvenation amid their busy schedules. On the other hand, diversifying the product range...
PR Newswire
15/04/2024
89th CMEF in Shanghai Elevates Global Medical Device Trade to The Next Level
This year, the exhibition featured nearly 5,000 renowned global enterprises with flagship products on display. Diverse categories were designed to explore emerging trends and prospects. Key categories include: This year, the exhibition featured nearly 5,000 renowned global enterprises with flagship products on display. Diverse categories were designed to explore emerging trends and prospects. Key categories include: This year, CMEF kicked off onApril 11th, coinciding with World...
PR Newswire
15/04/2024
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 15 April 2024– On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. Under the...
Nasdaq GlobeNewswire
15/04/2024
135th Canton Fair Opens with Optimized Structure and Enhanced Global Trade…
The 135th Canton Fair has kicked off with great enthusiasm. For the latest information on this session of the Canton Fair, please register at https://invitation.cantonfair.org.cn/BuyerUser/RegisterUser?MediaType=16. The 135 thCanton Fair has kicked off with great enthusiasm. For the latest information on this session of the Canton Fair, please register athttps://invitation.cantonfair.org.cn/BuyerUser/RegisterUser?MediaType=16. Photo -...
PR Newswire
15/04/2024
London Research & Pharmaceuticals presents the advancement of LRP-661, their…
When compared against the currently available oral solution of cannabidiol in a sesame oil suspension, CBDS shows no effect on gastrointestinal tolerability (no diarrhea) and no weight loss in animals, as well as no liver or renal toxicity and low affinity for many CYP-450 isozymes (such as 1A2, 3A4, 2B6) or P-glycoprotein (P-GP), which are responsible for many adverse drug-drug interactions.CBDS demonstrates high activity in several preclinical epilepsy models in which seizures are...
Nasdaq GlobeNewswire
15/04/2024
Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography…
BOSTON and LONDON, April15, 2024(GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the company will present new pre-clinical data on investigational long-acting PAS-nomacopan including drug effect on electroretinography (ERG) testing in a blue light model at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting in Seattle. Akari...
Nasdaq GlobeNewswire
15/04/2024
LG TARGETS EUROPEAN Built-in MARKET AT MILAN DESIGN WEEK 2024
Since the launch of its ultra-premium Signature Kitchen Suite built-in appliances, LG has continuously and strategically expanded its presence around the globe. Last year's IFA exhibition in Germany marked the introduction of the built-in lineups from LG brand, which complement the company's well-established ultra-premium offerings. At Milan Design Week 2024, the company seeks to demonstrate its commitment to providing premier culinary lifestyles, with a diverse range of products designed to…
PR Newswire
15/04/2024
Invitation: Sobi's Q1 2024 report
The presentation can be followed live here or afterwards on sobi.com. The slides will be made available on sobi.com prior to the conference call. The presentation can be followed livehereor afterwards on sobi.com. The slides will be made available on sobi.com prior to the conference call. To participate in the conference call, please use the following dial-in details:Sweden : +46 8 5051 0031United Kingdom : +44 207 107 06 13United States : +1 631 570 56 13 For other countries,...
PR Newswire
15/04/2024
Transactions in Connection with Share Buy-back Program Genmab
Company Announcement COPENHAGEN, Denmark; April 15, 2024 – Genmab A/S (Nasdaq: GMAB).On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares.The share buy-back program is expected to be completed no later than December 16, 2024.The following transactions were executed under the program from April 8, 2024 to April 12, 2024: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)...
Nasdaq GlobeNewswire
15/04/2024
Gedeon Richter: Cariprazine shows effectiveness in the treatment for dual…
In addition, Richter organized two scientific sessions: the Product Theatre focused on the topic of "New treatment options for dual schizophrenia", and a Mini Symposium was organized on the topic of "Schizophrenia and the management of psychiatric comorbidities", such as affective, anxiety and substance use disorders. In addition, Richter organized two scientific sessions: the Product Theatre focused on the topic of " New treatment options for dual schizophrenia "…
PR Newswire
15/04/2024
EVERSANA Completes Integration of Healthware Group and Strengthens Its Global…
EVERSANA INTOUCH Healthware joins five full-service affiliates and four specialty affiliates serving clients across the globe with world-class strategy, next-generation branding and creative, and innovative solutions to propel the future of life science marketing. Combined, the network helps pharmaceutical, medical device, and emerging biotech companies globally launch products, expand market access, and solve unique geographic and market-specific challenges. EVERSANA INTOUCH Healthware joins...
PR Newswire
15/04/2024
TREEFROG PRESENTS DATA FROM THEIR PARKINSON'S CELL THERAPY PROGRAM AT THE…
Parkinson's disease is a complex neurodegenerative disorder that affects more than 10 million worldwide, characterized by the progressive loss of dopamine-producing neurons in the brain. This debilitating condition manifests primarily through a range of motor symptoms such as tremors, rigidity, and bradykinesia, as well as non-motor symptoms which can include cognitive impairment and mood disorders. Symptoms usually appear when between 60%-80% of dopaminergic neurons are already lost, so...
PR Newswire
15/04/2024
PHAXIAM Therapeutics announces enrolment of the first patient in the phase 1…
The study plans for the enrolment of 12 patients in 5 French clinical centersFirst study results expected in Q3 2024This study will enable an evaluation of the intravenous administration of phages, particularly adapted to targeting indications with very high medical stakes. Lyon (France) and Cambridge (MA, US), April 15, 2024 – 7:30am CEST - PHAXIAM Therapeutics (Nasdaq & Euronext: FR0011471135),today announces the enrolment of the 1 stpatient in the phase 1 clinical...
Nasdaq GlobeNewswire
15/04/2024
Ultimovacs ASA – Disclosure of voting rights of Annual General Meeting
Oslo, April 15, 2024:In connection with the Annual General Meeting of Ultimovacs ASA to be held on April 18, 2024, Jónas Einarsson, Chair of the Board of Directors, has so far received proxy based voting rights without voting instructions for 9,063,854 shares, representing 26.34% of the total voting rights in the company. The proxies are only valid for the Annual General Meeting on April 18, 2024. This information is subject of the disclosure requirements pursuant to section 5-12 of the...
Nasdaq GlobeNewswire
15/04/2024
[Ad hoc announcement pursuant to Art. 53 LR] Roche's Columvi meets primary…
Columvi, in combination with chemotherapy, demonstrated a statistically significant improvement in overall survival for people with relapsed or refractory diffuse large B-cell lymphoma Data from the STARGLO study will be submitted to health authorities and presented at an upcoming medical meeting Basel, 15 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the Phase III STARGLO study met its primary endpoint of overall survival. The study demonstrated that people with...
Nasdaq GlobeNewswire
15/04/2024
Mallinckrodt Announces 2024 Extracorporeal Immunomodulation Award
DUBLIN, April 14, 2024 /PRNewswire/ -- Mallinckrodt plc, a global specialty pharmacy company, today announced that submissions for its 2024 Extracorporeal Immunomodulation Award (EIA) will open on 13 April 2024 during the 50th Annual Meeting of the European Bone Marrow Transplant Meeting (EBMT), Europe's largest annual congress in blood and bone marrow transplantation and cellular therapies. In recognition of 30 years since clinicians first used ECP to successfully treat chronic GvHD,1…
PR Newswire
14/04/2024
Pioneering Cutting-Edge Technologies: High-End Medical Imaging Developer VITAL…
Revolutionizing conventional CT technology, PCCT adopts photon counting-based tomography using CZT (Cadmium Zinc Telluride, CdZnTe) detectors for photon counting and energy analysis, which allows accurate measurement and recording of each X-ray photon that passes through to reveal unparalleled details of internal structures. PCCT's direct imaging innovation transcends conventional CT imaging constraints of crosstalk, electronic noise, and energy mixing, significantly enhancing image resolution…
PR Newswire
13/04/2024
Altri Comunicati